Goldline Pharmaceutical Peer Comparison

BSE: 544759

₹32.00

₹-0.48 (-1.48%)

As on 19-Oct-2026IST

Market cap

₹31 Cr

Revenue (TTM)

₹31 Cr

P/E Ratio

7.5

P/B Ratio

1.3

Div. Yield

0 %

Edit

	Goldline Pharmaceutical	Entero Health	VijayPD Ceutical	Speciality Medicines	Medi-Caps
Market cap (₹ Cr)	31	6,558	164	147	32
Revenue (₹ Cr)	31	7,128	100	75	13
Net Profit (₹ Cr)	4.12	167.66	5.00	13.03	-1.78
Net Margin (%)	13.20	2.35	4.79	17.12	-8.71
RoE (%)	39.41	7.58	9.53	25.60	-1.56
Price to Earnings	7.46	52.30	32.80	11.26	--
Price-To-Book	1.28	3.78	3.13	2.06	0.29

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Goldline Pharmaceutical	Entero Health	VijayPD Ceutical	Speciality Medicines	Medi-Caps
Operating Revenue	31.20	6,591.21	100.23	75.29	12.45
Total Income	31.20	6,610.45	104.35	76.11	20.66
Total Expenditure	24.12	6,325.26	95.56	61.60	21.85
EBITDA	7.08	265.96	4.67	13.68	-9.40
Depreciation	0.24	43.29	0.65	0.17	1.81
EBIT	6.84	222.66	4.02	13.51	-11.21
Interest	1.46	54.39	1.66	1.32	0.02
Other Income	0.00	19.24	4.12	0.83	8.21
Exceptional Items	--	-8.18	-0.01	--	--
Profit before Tax	5.39	179.34	6.47	13.02	-3.02
Provision for Tax	1.27	33.50	1.47	-0.01	0.01
Profit after Tax	4.12	145.84	5.00	13.03	-3.04

Liabilities (₹ Cr)

	Goldline Pharmaceutical	Entero Health	VijayPD Ceutical	Speciality Medicines	Medi-Caps
Shareholder's Funds	14.25	1,688.61	52.48	71.19	111.61
Minority Interest	--	63.94	-0.08	--	--
Non-Current Liabilities	2.43	206.12	4.66	5.15	1.14
Current Liabilities	12.11	1,587.57	42.23	18.88	2.71
Total Liabilities	28.87	3,600.22	99.64	95.22	115.46

Assets (₹ Cr)

	Goldline Pharmaceutical	Entero Health	VijayPD Ceutical	Speciality Medicines	Medi-Caps
Non-Current Assets	2.75	1,037.80	23.77	6.26	68.44
Current Assets	26.05	2,503.13	75.53	88.97	47.02
Total Assets	28.87	3,600.22	99.64	95.22	115.46
Total Debt*	9.16	566.68	36.71	6.64	0.00
Net Current Assets	13.93	915.56	33.30	70.09	44.31
Contingent Liabilities	3.37	5.51	0.14	--	--

Cashflow (₹ Cr)

	Goldline Pharmaceutical	Entero Health	VijayPD Ceutical	Speciality Medicines	Medi-Caps
Cash From Operating Activities	2.81	96.20	-8.61	-1.28	-7.02
Cash Flow from Investing Activities	-0.06	-303.06	-13.33	-2.83	7.11
Cash from Financing Activities	-3.40	123.66	31.59	27.82	--
Net Cash Inflow / Outflow	-0.65	-83.20	9.65	23.70	0.09

Ratios

Profitability Ratios

	Goldline Pharmaceutical	Entero Health	VijayPD Ceutical	Speciality Medicines	Medi-Caps
ROCE (%)	30.60	10.93	9.12	25.26	-2.58
ROE (%)	39.41	8.57	9.53	25.60	-2.61
ROA (%)	14.98	4.68	5.04	19.27	-2.52
EBIT Margin (%)	22.70	4.33	8.77	19.27	-9.59
Net Margin (%)	13.20	2.21	4.79	17.12	-14.70
Cash Profit Margin (%)	13.97	2.87	5.64	17.54	-9.88

Growth Ratios

	Goldline Pharmaceutical	Entero Health	VijayPD Ceutical	Speciality Medicines	Medi-Caps
Revenue Growth (%)	11.20	29.35	0.00	29.20	-51.14
EBIT Growth (%)	16.95	35.13	--	54.39	-229.03
Net Profit Growth (%)	45.26	35.75	0.00	81.11	-431.96
EPS Growth (%)	45.26	21.32	0.00	32.67	-431.95
Book Value Growth (%)	47.19	-2.19	0.00	132.49	-7.97

Valuation Ratios

	Goldline Pharmaceutical	Entero Health	VijayPD Ceutical	Speciality Medicines	Medi-Caps
Price / Earnings	0.00	47.12	25.46	8.49	0.00
Price / Book Value	0.00	3.22	2.43	1.55	0.26
Dividend Yield (%)	--	0.00	0.00	0.00	0.00
EV/EBITDA	2.44	20.43	16.66	6.39	-23.82
Market Cap (₹ Cr)	0.00	5,420.61	127.33	110.62	28.93

Solvency Ratios

	Goldline Pharmaceutical	Entero Health	VijayPD Ceutical	Speciality Medicines	Medi-Caps
Debt to Equity	0.64	0.34	0.70	0.09	0.00
Short term debt to equity ratio	0.42	0.26	0.48	0.01	--
Current Ratio	2.15	1.58	1.79	4.71	17.34
Quick Ratio	1.64	1.05	1.49	3.21	16.26
Interest Coverage	4.70	4.30	4.89	10.87	-137.05

Operating Efficiency Ratios

	Goldline Pharmaceutical	Entero Health	VijayPD Ceutical	Speciality Medicines	Medi-Caps
Debtors to sales (%)	51.70	18.39	30.52	35.20	55.60
Asset Turnover	1.13	2.11	1.01	1.11	0.10
Receivable days	156.90	56.56	111.39	87.52	230.34
Inventory Days	75.99	41.57	45.39	110.76	90.05
Payable days	64.86	34.66	32.72	43.45	71.74
Cash Conversion Cycle	168.03	63.47	124.06	154.84	248.65

Annual
Quarterly